Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis secures further Australian government reimbursement for Bronchitol

Pharmaxis is a global leader in drug development for fibrosis and inflammation.
Pharmaxis secures further Australian government reimbursement for Bronchitol
The company is well-funded with $39 million in cash at the end of September

Pharmaxis Ltd (ASX:PXS) has achieved extended reimbursement of its drug Bronchitol (mannitol) on the Pharmaceutical Benefits Scheme (PBS).

This means that from the start of 2018, eligible people with cystic fibrosis who are taking Pulmozyme® (dornase alfa), another CF (cystic fibrosis) medication, will be able to add reimbursed Bronchitol to their treatment regime.

Cystic fibrosis is a genetic condition affecting one in every 2500 Australian babies.

People with the condition develop an abnormal amount of excessively thick and sticky mucus within their lungs, airways and the digestive system.

What is Bronchitol

Bronchitol has an active ingredient in mannitol, which is delivered as an inhalable dry powder to restore the airway surface liquid.

Other benefits include enhanced mucus clearance, improved lung function while reducing incidence of lung infections.

Bronchitol has been studied in more than 1000 clinical trial patients4 and is indicated for appropriate CF patients over six years of age.

Pharmaxis plans for a Bronchitol FDA re-submission by Chiesi in 2018.

Chiesi is the distributor for the major EU markets.

Importance of the listing on PBS

This new listing will allow clinicians treating cystic fibrosis to use two agents that work differently, and are proven to work together in the CF lung, to improve mucus clearance.

PBS reimbursement of this combined treatment approach will also significantly reduce paperwork for CF treating teams and improve access for patients.

Gary Phillips, chief executive officer for Pharmaxis, commented:

"We are delighted that more Australians with cystic fibrosis will now have access to treatment with Bronchitol under this expanded listing.

"We are proud that a locally developed and manufactured product is helping people living with this incurable disease."

An expanded PBS listing for Bronchitol was supported by the CF community, healthcare professionals and Cystic Fibrosis Australia in submissions to the government committee advising on medicine reimbursement.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use